

Committee on the Evidence Base for Lyme Infection-Associated Chronic Illnesses Treatment

MEETING AGENDA

August 12-13, 2024

Meeting Objectives:

Open Session

- Discuss the current evidence in understanding the etiology and potential treatment of Lyme IACI.
- Examine issues of health equity and ethical considerations in Lyme IACI research and discuss implications for a future research agenda toward treatment development.

DAY 1 – MONDAY, AUGUST 12, 2024

CLOSED SESSION

9:00 AM

Committee meets in closed session

OPEN SESSION

WELCOME

9:45 AM

Welcome & opening remarks
KENT KESTER, *Committee Chair*
Executive Director of Vaccine R&D
CEPI

SESSION 1 Moving toward Treatments: Remaining Questions in Lyme IACI Research

Session Objective:

- Identify unresolved research questions on the etiology of Lyme IACI that can inform treatment development and discuss key actions necessary to fill this knowledge gap.

9:50 AM

Evidence for central nervous system involvement in Lyme IACI
BRIAN FALLON
Professor, Psychiatry
Director
Center for Neuroinflammatory Disorders and Biobehavioral Medicine

	Lyme and Tick-Borne Diseases Research Center Columbia University Vagelos College of Physicians and Surgeons
10:00 AM	Pathogen persistence and host immune response MONICA EMBERS Associate Professor, Microbiology and Immunology Director of Vector-Borne Disease Research Tulane School of Medicine LINDA BOCKENSTEDT Harold W. Jockers Professor of Medicine Yale School of Medicine
10:20 AM	Microbiome dysbiosis ILHEM MESSAOUDI POWERS Professor and Chair Department of Microbiology, Immunology and Molecular Genetics University of Kentucky, College of Medicine
10:30 AM	Discussion: clinician perspective on challenges in clinical diagnosis and treatment outcomes RAVINDRA GANESH Associate Professor of Medicine Medical Director Post COVID Care Clinic at Mayo Clinic RYAN HURT Professor of Medicine Director, Post-COVID Research and Practice Mayo Clinic LISA SANDERS Professor of Medicine Medical Director Yale New Haven Health Systems Long COVID Consultation Clinic
10:45 AM	Open discussion with committee
11:30 AM	BREAK
CLOSED SESSION	
12:00 PM	Committee meets in closed session
2:00 PM	ADJOURN DAY 1

DAY 2 – TUESDAY, AUGUST 13, 2024

OPEN SESSION

WELCOME

9:00 AM

Welcome/Opening

KENT KESTER, *Committee Chair*
Executive Director of Vaccine R&D
CEPI

SESSION 2 Health Equity Considerations for Future Research Agenda

Objectives:

- Examine unique challenges in working with underserved populations for research studies on Lyme IACI treatment and discuss mitigation strategies.
- Examine what is known about co-infections with other tick-borne pathogens and the relevance for developing new treatments and diagnostics for Lyme IACI.
- Elucidate current understanding of additional risk factors in developing Lyme IACI from acute Lyme disease and identify promising research directions.

9:05 AM

Underserved populations

ROBERTA DEBIASI
Robert H. Parrott Professor of Pediatric Research
Children's National Hospital
Principal Investigator
Children's National Research Institute

BETHANY ALCAUTER
Director of Research and Public Health Programs
National Center for Farmworker Health

9:25 AM

Additional risk factors in developing Lyme IACI

Host risk factors including sex differences

MICHAL TAL
Principal Scientist, Department of Biological Engineering
Associate Scientific Director, Center for Gynepathology Research
Massachusetts Institute of Technology

Role of environmental exposures

ESTHER MELAMED
Assistant Professor, Neurology
University of Texas at Austin, Dell Medical School

Co-infections and potential interplay of immune responses

EROL FIKRIG

Waldemar Von Zedtwitz Professor of Medicine

Professor of Epidemiology

Professor of Microbial Pathogenesis

Yale School of Medicine

9:55 AM

Open discussion with committee

10:15 AM

BREAK

CLOSED SESSION

10:30 AM

Committee meets in closed session

2:30 PM

ADJOURN